Supportive Care

For Holly G. Prigerson, PhD, Psychosocial Issues Are at the Heart of End-of-Life Cancer Care

Holly G. Prigerson, PhD, Co-Director of the Weill Cornell Medicine’s Center for Research on End-of-Life Care, was born in Maimonides Hospital in Brooklyn...

Breast Cancer

Adjuvant Zoledronic Acid in Early Breast Cancer: Is 5 Years Better?

The phase III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid...

Issues in Oncology

FDA Takes Steps to Improve Transparency in Clinical Trial Information Related to New Drugs

As part of the U.S. Food and Drug Administration’s (FDA) efforts to enhance transparency around its drug-approval decisions, the FDA is exploring new ways...


More Top Stories

Hematologic Malignancies
Issues in Oncology
Cost of Care

Alok A. Khorana, MD, on The Costs of VTE in Cancer Patients: Expert Perspective

Multiple Myeloma

For Patients Treated for Myeloma, Antibiotic Prophylaxis May Reduce Infections and Deaths

IN PATIENTS undergoing treatment of multiple myeloma, the prophylactic use of levofloxacin significantly reduced febrile episodes and deaths, without increasing healthcare-associated infections or carriage of key nosocomial pathogens, in a large multicenter study from the United Kingdom.1 The...


2018 GU CANCERS SYMPOSIUM: Tivozanib in Combination With Nivolumab in Metastatic RCC

Preliminary results from the phase II portion of the TiNivo study, a phase Ib/II multicenter trial of oral tivozanib in combination with intravenous (IV) nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma (RCC) were presented by Escudier et al at the 2018 Genitourinary Cancers...

Hepatobiliary Cancer

Ghassan K. Abou-Alfa, MD, on HCC: Results From the CELESTIAL Trial

Global Cancer Care

Changing Negative Perceptions on the Impact of Clinical Trials in Brazil

CLINICAL TRIALS are an essential research tool to advance medical knowledge and patient care. Traditionally, the majority of pharmaceutical-sponsored clinical trials have been implemented in Western Europe and North America. More recently, however, large pharmaceutical companies have increased...

Supportive Care
Integrative Oncology

The State of Integrative Oncology: A New Era

Now that we have entered 2018, let’s take a moment to reflect on how far we have come and what lies ahead in integrative oncology care. Overview To cope with the physical, emotional, and spiritual effects of cancer, and in search of relief from symptoms that their conventional treatments have not...

ASCO Examines the Current Oncology Clinical Pathways Landscape

ASCO has released its review of leading oncology pathway vendors in the United States. “Oncology Clinical Pathways: Charting the Landscape of Pathway Providers,” published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using...

Multiple Myeloma

Maria-Victoria Mateos, MD, PhD, on Multiple Myeloma: Results From the ALCYONE Trial

Issues in Oncology

Up-to-Date Labels for Older Drugs Essential for Appropriate Use

  Oncology drug labels, especially those that have been on the market for more than 15 years, may not always be up-to-date. Critical data about safety, efficacy, or prescribing information may be missing. Modernizing the labeling process can correct inaccurate information, add data for indications ...


ASCO and NCCN Provide Guidelines for Managing Immunotherapy Side Effects

Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into...